Disulfiram repurposing combined with nutritional copper supplement as add-on to chemotherapy in recurrent glioblastoma (DIRECT): Study protocol for a randomized controlled trial

Asgeir Store Jakola, Katja Werlenius, Munila Mudaisi, Sofia Hylin, Sara Kinhult, Jiri Bartek Jr, Øyvind Salvesen, Sven Magnus Carlsen, Michael Strandéus, Magnus Lindskog, David Löfgren, Bertil Rydenhag, Louise Carstam, Sasha Gulati, Ole Solheim, Jiri Bartek, Tora Solheim, Asgeir Store Jakola, Katja Werlenius, Munila Mudaisi, Sofia Hylin, Sara Kinhult, Jiri Bartek Jr, Øyvind Salvesen, Sven Magnus Carlsen, Michael Strandéus, Magnus Lindskog, David Löfgren, Bertil Rydenhag, Louise Carstam, Sasha Gulati, Ole Solheim, Jiri Bartek, Tora Solheim

Abstract

Background: Disulfiram (DSF) is a well-tolerated, inexpensive, generic drug that has been in use to treat alcoholism since the 1950s. There is now independent preclinical data that supports DSF as an anticancer agent, and experimental data suggest that copper may increase its anti-neoplastic properties. There is also some clinical evidence that DSF is a promising anticancer agent in extracranial cancers. In glioblastoma, DSF induced O 6-methylguanine methyltransferase (MGMT) inhibition may increase response to alkylating chemotherapy. A recent phase I study demonstrated the safety of DSF in glioblastoma patients when DSF was administered at doses below 500 mg/day together with chemotherapy. We plan to assess the effects of DSF combined with nutritional copper supplement (DSF-Cu) as an adjuvant to alkylating chemotherapy in glioblastoma treatment. Methods: In an academic, industry independent, multicenter, open label randomized controlled phase II/III trial with parallel group design (1:1) we will assess the efficacy and safety of DSF-Cu in glioblastoma treatment. The study will include 142 patients at the time of first recurrence of glioblastoma where salvage therapy with alkylating chemotherapy is planned. Patients will be randomized to treatment with or without DSF-Cu. Primary end-point is survival at 6 months. Secondary end-points are overall survival, progression free survival, quality of life, contrast enhancing tumor volume and safety. Discussion: There is a need to improve the treatment of recurrent glioblastoma. Results from this randomized controlled trial with DSF-Cu in glioblastoma will serve as preliminary evidence of the future role of DSF-Cu in glioblastoma treatment and a basis for design and power estimations of future studies. In this publication we provide rationale for our choices and discuss methodological issues. Trial registration: The study underwent registration in EudraCT 2016-000167-16 (Date: 30.03.2016,) and Clinicaltrials.gov NCT02678975 (Date: 31.01.2016) before initiating the study.

Keywords: Randomized controlled trial; alkylating agents; brain tumor; disulfiram; glioblastoma; glioma.

Conflict of interest statement

No competing interests were disclosed.

Figures

Figure 1.. Flow-chart of patient screening, inclusion…
Figure 1.. Flow-chart of patient screening, inclusion and follow-up.

References

    1. Rønning PA, Helseth E, Meling TR, et al. : A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. Neuro Oncol. 2012;14(9):1178–1184. 10.1093/neuonc/nos153
    1. Stupp R, Mason WP, van den Bent MJ, et al. : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. 10.1056/NEJMoa043330
    1. Hegi ME, Liu L, Herman JG, et al. : Correlation of O 6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26(25):4189–4199. 10.1200/JCO.2007.11.5964
    1. Seystahl K, Wick W, Weller M: Therapeutic options in recurrent glioblastoma--An update. Crit Rev Oncol Hematol. 2016;99:389–408. 10.1016/j.critrevonc.2016.01.018
    1. Weller M, van den Bent M, Hopkins K, et al. : EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014;15(9):e395–403. 10.1016/S1470-2045(14)70011-7
    1. Taal W, Oosterkamp HM, Walenkamp AM, et al. : Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15(9):943–953. 10.1016/S1470-2045(14)70314-6
    1. Collins FS: Mining for therapeutic gold. Nat Rev Drug Discov. 2011;10(6):397. 10.1038/nrd3461
    1. Chick J: Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf. 1999;20(5):427–435. 10.2165/00002018-199920050-00003
    1. Huang J, Campian JL, Gujar AD, et al. : A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy. J Neurooncol. 2016;128(2):259–66. 10.1007/s11060-016-2104-2
    1. Chen D, Cui QC, Yang H, et al. : Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res. 2006;66(21):10425–10433. 10.1158/0008-5472.CAN-06-2126
    1. Kast RE, Boockvar JA, Bruning A, et al. : A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget. 2013;4(4):502–530. 10.18632/oncotarget.969
    1. Liu P, Brown S, Goktug T, et al. : Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. Br J Cancer. 2012;107(9):1488–1497. 10.1038/bjc.2012.442
    1. Loo TW, Bartlett MC, Clarke DM: Disulfiram metabolites permanently inactivate the human multidrug resistance P-glycoprotein. Mol Pharm. 2004;1(6):426–433. 10.1021/mp049917l
    1. Rae C, Tesson M, Babich JW, et al. : The role of copper in disulfiram-induced toxicity and radiosensitization of cancer cells. J Nucl Med. 2013;54(6):953–960. 10.2967/jnumed.112.113324
    1. Triscott J, Lee C, Hu K, et al. : Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. Oncotarget. 2012;3(10):1112–1123. 10.18632/oncotarget.604
    1. Westhoff MA, Zhou S, Nonnenmacher L, et al. : Inhibition of NF-κB signaling ablates the invasive phenotype of glioblastoma. Mol Cancer Res. 2013;11(12):1611–1623. 10.1158/1541-7786.MCR-13-0435-T
    1. Lun X, Wells JC, Grinshtein N, et al. : Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma. Clin Cancer Res. 2016;22(15):3860–75. 10.1158/1078-0432.CCR-15-1798
    1. Hothi P, Martins TJ, Chen L, et al. : High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells. Oncotarget. 2012;3(10):1124–1136. 10.18632/oncotarget.707
    1. Paranjpe A, Zhang R, Ali-Osman F, et al. : Disulfiram is a direct and potent inhibitor of human O 6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage. Carcinogenesis. 2014;35(3):692–702. 10.1093/carcin/bgt366
    1. Skrott Z, Mistrik M, Andersen KK, et al. : Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature. 2017;552(7684):194–199. 10.1038/nature25016
    1. Kast RE, Karpel-Massler G, Halatsch ME: CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. Oncotarget. 2014;5(18): 8052–8082. 10.18632/oncotarget.2408
    1. Karnofsky DA, Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer. New York: Columbia University Press.1949;191–205.
    1. European Food Safety Authority: Tolerable upper intake levels for vitamins and minerals.
    1. EuroQol Group: EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208. 10.1016/0168-8510(90)90421-9
    1. Stensjøen AL, Solheim O, Kvistad KA, et al. : Growth dynamics of untreated glioblastomas in vivo. Neuro Oncol. 2015;17(10):1402–11. 10.1093/neuonc/nov029
    1. Khan I, Sarker SJ, Hackshaw A: Smaller sample sizes for phase II trials based on exact tests with actual error rates by trading-off their nominal levels of significance and power. Br J Cancer. 2012;107(11):1801–1809. 10.1038/bjc.2012.444
    1. Sagberg LM, Solheim O, Jakola AS: Quality of survival the 1st year with glioblastoma: a longitudinal study of patient-reported quality of life. J Neurosurg. 2015;124(4):989–97. 10.3171/2015.4.JNS15194
    1. Wen PY, Macdonald DR, Reardon DA, et al. : Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–1972. 10.1200/JCO.2009.26.3541
    1. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. Bethesda, USA.2010.
    1. Chan AW, Tetzlaff JM, Gøtzsche PC, et al. : SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. 10.1136/bmj.e7586
    1. Schulz KF, Altman DG, Moher D, et al. : CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010;11:32. 10.1186/1745-6215-11-32
    1. World Medical Association: World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects JAMA. 2013;310(20):2191–2194. 10.1001/jama.2013.281053
    1. Ford I, Norrie J: Pragmatic Trials. N Engl J Med. 2016;375(5):454–463. 10.1056/NEJMra1510059

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する